EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY 4.0

Cardioprotection with Intralipid During Coronary Artery Bypass Grafting Surgery on Cardiopulmonary Bypass: A Randomized Clinical Trial

Nkanyiso Hadebe, Martin Cour, Aqeela Imamdin, Tarra Petersen, Timothy Pennel, Jacques Scherman, Jane Snowball, Mpiko Ntsekhe, Peter Zilla, Justiaan Swanevelder, Sandrine Lecour iD

Cardiovascular Drugs and Therapy · 2025

DOI: 10.1007/s10557-024-07594-w ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Cardiovascular Drugs and Therapy, 2025. Verfasst von Nkanyiso Hadebe und 10 weiteren Autor:innen. Beteiligte Einrichtung: Cardioprotection Group, Faculty of Health Sciences, Cape Heart Institute, University of Cape Town, Anzio Road, Cape Town, 7925, Observatory, South Af…. Hauptthemen laut MEDLINE: Coronary Artery Bypass, Cardiopulmonary Bypass, Phospholipids, Myocardial Reperfusion Injury. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: University of Cape Town, South African National Research Foundation, Ernest Oppenheimer Memorial Trust.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Coronary artery bypass grafting (CABG) on cardiopulmonary bypass (CPB) is associated with myocardial ischemia–reperfusion injury (IRI), which may limit the benefit of the surgery. Both experimental and clinical studies suggest that Intralipid, a lipid emulsion commonly used for parenteral nutrition, can limit myocardial IRI. We therefore aimed to investigate whether Intralipid administered at reperfusion can reduce myocardial IRI in patients undergoing CABG on CPB.

Methods

We conducted a randomized, double-blind, pilot trial in which 29 adult patients scheduled for CABG were randomly assigned (on a 1:1 basis) to receive either 1.5 ml/kg Intralipid 20% or Ringer’s Lactate 3 min before aortic cross unclamping. The primary endpoint was the 72-h area under the curve (AUC) for troponin I.

Results

Of the 29 patients randomized, 26 were included in the study (two withdrew consent and one was excluded before surgery). The 72-h AUC for troponin I did not significantly differ between the control and Intralipid group (546437 ± 205518 versus 487561 ± 115724 arbitrary units, respectively; P = 0.804). Other outcomes (including 72-h AUC for CK-MB, C-reactive protein, need for defibrillation, time to extubation, length of ICU and hospital stay, and serious adverse events) were similar between the two groups.

Conclusion

In patients undergoing CABG on CPB, Intralipid did not limit myocardial IRI compared to placebo. Trial Registration ClinicalTrials.gov Identifier: NCT02807727 (registration date: 16 June 2016).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Coronary Artery BypassCardiopulmonary BypassPhospholipidsMyocardial Reperfusion InjuryFat Emulsions, IntravenousSoybean OilCardiotonic AgentsHumansMaleDouble-Blind MethodFemaleMiddle AgedAgedPilot ProjectsEmulsionsTroponin ITreatment OutcomeRinger's Lactate

Stichwörter der Autor:innen

CardioprotectionCoronary artery bypass graftingIntralipidIschemia–reperfusion injury

Substanzen

EmulsionsPhospholipidsFat Emulsions, Intravenoussoybean oil, phospholipid emulsionTroponin ISoybean OilCardiotonic AgentsRinger's Lactate

Autor:innen und Institutionen

  • Cardioprotection Group, Faculty of Health Sciences, Cape Heart Institute, University of Cape Town, Anzio Road, Cape Town, 7925, Observatory, South Africa.
  • Department of Anaesthesia, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa.
  • Chris Barnard Division of Cardiothoracic Surgery, University of Cape Town, Cape Town, South Africa.
  • Division of Cardiology, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa.
  • Cardioprotection Group, Faculty of Health Sciences, Cape Heart Institute, University of Cape Town, Anzio Road, Cape Town, 7925, Observatory, South Africa. sandrine.lecour@uct.ac.za.

ORCID-Profile: Sandrine Lecour

Förderung

  • University of Cape Town
  • South African National Research Foundation
  • Ernest Oppenheimer Memorial Trust
  • Discovery Foundation
  • South African Medical Research Council

Zitieren

APA

Hadebe, N., Cour, M., Imamdin, A., Petersen, T., Pennel, T., Scherman, J., Snowball, J., Ntsekhe, M., Zilla, P., Swanevelder, J., & Lecour, S. (2025). Cardioprotection with Intralipid During Coronary Artery Bypass Grafting Surgery on Cardiopulmonary Bypass: A Randomized Clinical Trial. Cardiovascular Drugs and Therapy. https://doi.org/10.1007/s10557-024-07594-w

Vancouver

Hadebe N, Cour M, Imamdin A, Petersen T, Pennel T, Scherman J, et al. Cardioprotection with Intralipid During Coronary Artery Bypass Grafting Surgery on Cardiopulmonary Bypass: A Randomized Clinical Trial. Cardiovascular Drugs and Therapy. 2025. doi:10.1007/s10557-024-07594-w

BibTeX
@article{Hadebe2025,
  author = {Hadebe, Nkanyiso and Cour, Martin and Imamdin, Aqeela and Petersen, Tarra and Pennel, Timothy and Scherman, Jacques and Snowball, Jane and Ntsekhe, Mpiko and Zilla, Peter and Swanevelder, Justiaan and Lecour, Sandrine},
  title = {Cardioprotection with Intralipid During Coronary Artery Bypass Grafting Surgery on Cardiopulmonary Bypass: A Randomized Clinical Trial},
  journal = {Cardiovascular Drugs and Therapy},
  year = {2025},
  doi = {10.1007/s10557-024-07594-w}
}
Kostenlos starten →